Aastrom announces first patients treated in ixCELL-DCM clinical study of ixmyelocel-T Aastrom Biosciences announced that the first patients were treated in the ixCELL-DCM Phase 2b clinical trial. This study is evaluating the safety and efficacy of ixmyelocel-T compared to placebo in patients with advanced heart failure due to ischemic dilated cardiomyopathy. Aastrom has received U.S. orphan drug designation for the use of ixmyelocel-T in patients with DCM.
News For ASTM From The Last 14 Days
Check below for free stories on ASTM the last two weeks.